About TherapeuticsMD (NASDAQ:TXMD)
TherapeuticsMD, Inc. is a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the vitaMedMD and BocaGreenMD brands. TherapeuticsMD was founded by Robert G. Finizio and Brian A. Bernick in 2008 and is headquartered in Boca Raton, FL.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TXMD
CUSIPN/A
Phone561-961-1900
Debt
Debt-to-Equity RatioN/A
Current Ratio10.48%
Quick Ratio10.37%
Price-To-Earnings
Trailing P/E Ratio-15.35
Forward P/E Ratio-14.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.78 million
Price / Sales73.12
Cash FlowN/A
Price / CashN/A
Book Value$0.60 per share
Price / Book9.45
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-76,920,000.00
Net Margins-458.49%
Return on Equity-63.67%
Return on Assets-57.53%
Miscellaneous
Employees173
Outstanding Shares216,400,000
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) announced its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $4.66 million. TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The business's quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.12) earnings per share. View TherapeuticsMD's Earnings History.
What price target have analysts set for TXMD?
9 Wall Street analysts have issued 1-year target prices for TherapeuticsMD's shares. Their forecasts range from $6.00 to $28.00. On average, they anticipate TherapeuticsMD's stock price to reach $14.50 in the next year. View Analyst Ratings for TherapeuticsMD.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 57,501,783 shares, an increase of 0.8% from the March 15th total of 57,941,715 shares. Based on an average trading volume of 1,926,644 shares, the days-to-cover ratio is currently 29.8 days. Currently, 33.1% of the company's shares are short sold.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Akorn (AKRX), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Cambrex (CBM), Insmed (INSM) and MyoKardia (MYOK).
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Robert G. Finizio, Chief Executive Officer & Director
- John C. K. Milligan, President & Director
- Daniel Alan Cartwright, Chief Financial Officer, Treasurer & VP
- Brian A. Bernick, Director & Chief Clinical Officer
- Sebastian Mirkin, Chief Medical Officer
Has TherapeuticsMD been receiving favorable news coverage?
Headlines about TXMD stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TherapeuticsMD earned a news sentiment score of 0.16 on Accern's scale. They also gave news articles about the company an impact score of 44.73 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $5.67.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $1.24 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
TherapeuticsMD (NASDAQ:TXMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for TherapeuticsMD in the last 12 months. Their average twelve-month price target is $14.50, suggesting that the stock has a possible upside of 155.73%. The high price target for TXMD is $28.00 and the low price target for TXMD is $6.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.89 | 2.89 | 2.89 | 2.91 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.50 | $14.50 | $14.50 | $16.25 |
| Price Target Upside: | 155.73% upside | 184.31% upside | 124.81% upside | 234.36% upside |
TherapeuticsMD (NASDAQ:TXMD) Consensus Price Target History
TherapeuticsMD (NASDAQ:TXMD) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
TherapeuticsMD (NASDAQ:TXMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
TherapeuticsMD (NASDAQ TXMD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 23.92%
Institutional Ownership Percentage: 73.37%
TherapeuticsMD (NASDAQ TXMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/8/2017 | Tommy G Thompson | Director | Buy | 5,000 | $6.21 | $31,050.00 | 3,555 |  |
| 8/30/2017 | Tommy G Thompson | Director | Buy | 5,000 | $5.99 | $29,950.00 | 3,555 | |
| 3/11/2016 | Cooper C Collins | Director | Buy | 16,000 | $6.23 | $99,680.00 | 36,000 | |
| 8/25/2015 | Angus C Russell | Director | Buy | 13,500 | $5.98 | $80,730.00 | 48,500 | |
| 6/8/2015 | Mitchell Krassan | EVP | Sell | 30,000 | $8.18 | $245,400.00 | | |
| 5/12/2015 | Angus C Russell | Director | Buy | 35,000 | $6.15 | $215,250.00 | | |
| 5/11/2015 | Tommy G Thompson | Chairman | Buy | 6,000 | $6.09 | $36,540.00 | | |
| 5/8/2015 | J Martin Carroll | Director | Buy | 10,000 | $6.11 | $61,100.00 | | |
| 11/21/2014 | Daniel A Cartwright | CFO | Sell | 40,000 | $3.91 | $156,400.00 | | |
| 9/4/2014 | Tommy G Thompson | Director | Buy | 1,757 | $5.44 | $9,558.08 | | |
| 6/5/2014 | Cooper C Collins | Director | Buy | 20,000 | $3.84 | $76,800.00 | | |
| 5/9/2014 | Robert Lapenta, Jr. | Director | Buy | 5,000 | $3.66 | $18,300.00 | 10,000 | |
| 5/8/2014 | Tommy Thompson | Director | Buy | 14,000 | $3.57 | $49,980.00 | | |
| 3/26/2014 | Brian Bernick | Director | Sell | 421,268 | $6.70 | $2,822,495.60 | 297,000 | |
| 3/26/2014 | John C.K. Iv Milligan | Insider | Sell | 353,412 | $6.70 | $2,367,860.40 | 1,722,419 | |
| 3/26/2014 | Robert Finizio | CEO | Sell | 982,053 | $6.70 | $6,579,755.10 | 21,029,533 | |
| 3/10/2014 | Mitchell Krassan | EVP | Sell | 7,500 | $7.73 | $57,975.00 | | |
| 2/26/2014 | John C.K. Iv Milligan | President | Sell | 25,000 | $6.31 | $157,750.00 | 6,318,018 | |
| 2/21/2014 | Robert Finizio | CEO | Sell | 50,000 | $6.17 | $308,500.00 | 22,011,586 | |
| 2/12/2014 | Brian Bernick | Director | Sell | 31,250 | $6.16 | $192,500.00 | | |
| 1/30/2014 | John C.K. Iv Milligan | Insider | Sell | 25,000 | $6.16 | $154,000.00 | 6,343,018 | |
| 1/23/2014 | Robert G Finizio | CEO | Sell | 50,000 | $5.70 | $285,000.00 | | |
| 1/13/2014 | Mitchell Krassan | EVP | Sell | 7,500 | $5.73 | $42,975.00 | | |
| 1/8/2014 | Brian Bernick | Director | Sell | 31,250 | $5.13 | $160,312.50 | | |
| 8/26/2013 | Brian Bernick | Insider | Sell | 1,600,000 | $1.55 | $2,480,000.00 | | |
| 8/26/2013 | Jules A Musing | Director | Buy | 5,282 | $2.15 | $11,356.30 | | |
| 6/14/2013 | Cooper C Collins | Director | Sell | 2,631,579 | $1.75 | $4,605,263.25 | | |
(Data available from 1/1/2013 forward)
TherapeuticsMD (NASDAQ TXMD) News Headlines
| Source: |
|
TherapeuticsMD (NASDAQ:TXMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
TherapeuticsMD (NASDAQ:TXMD) Income Statement, Balance Sheet and Cash Flow Statement
TherapeuticsMD (NASDAQ TXMD) Stock Chart for Monday, April, 23, 2018
Loading chart…
